We found that the expression of SDCBP2 was significantly upregulated in Cervical Cancer (CESC), Bile Duct Cancer (CHOL), Kidney Chromophobe (KICH), Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Pheochromocytoma & Paraganglioma (PCPG), and Endometrioid Cancer (UCEC), and significantly downregulated in Colon Cancer (COAD), Glioblastoma (GBM), Head and Neck Cancer (HNSC), Kidney Papillary Cell Carcinoma (KIRP), Prostate Cancer (PRAD), Rectal Cancer (READ), and Thyroid Cancer (THCA) (Figures 2A, B). Here, SDCBP2 is linked to prostate carcinoma.